Navigation Links
Oral Vaccine May Help People With COPD
Date:4/6/2010

Preliminary results suggest a new option to treat the breathing disease

TUESDAY, April 6 (HealthDay News) -- An experimental vaccine for chronic obstructive pulmonary disease (COPD), a progressive respiratory disease that afflicts millions of people, may reduce flare-ups in those with severe forms of the illness, new research finds.

Unlike regular childhood vaccinations or the flu shot, this vaccine, which is made from the bacteria that causes meningitis in children, does not prevent COPD but rather tames the severity, duration and frequency of flare-ups.

"It's not an ideal study but it is suggestive that using this novel oral vaccine can reduce the number of serious COPD exacerbations," said Dr. Norman H. Edelman, chief medical officer of the American Lung Association. "That's a very significant finding and could be a very, very useful tool in the management of severe COPD."

Dr. Len Horovitz, a pulmonary specialist with Lenox Hill Hospital in New York City, added, "they're modest results but certainly favorable and it would seem to be non-toxic."

COPD, which is usually caused by smoking, is the fourth leading cause of death in the United States and, said Edelman, is "a major, major problem."

Currently available treatments include flu and pneumonia shots to prevent infection, and oxygen and medications to improve quality of life. It's unclear if any of these interventions actually prolong life, Edelman said.

"There's not a lot new under the sun," Horovitz said.

Flare-ups of COPD seem to be caused by the wrong bacteria or the wrong proportion of bacteria in the airways, which results in inflammation.

"This [new study] is capitalizing on the theory that the inflammation responses due to colonization of bacteria is different in COPD," Horovitz explained."

The vaccine studied in the new trial, HI-164OV, is made from inactivated Haemophilus influenzae, the bacteria responsible for meningitis in children. The study authors, from Australia, were hoping that this inactivated bacteria would trigger a beneficial change in bacteria colonization.

The trial was a small one, involving only 38 people, all with severe COPD. The patients were randomly selected to receive either the new HI-164OV oral vaccine or a placebo along with best available treatment.

The study showed encouraging results.

Although overall COPD exacerbations only went down by 16 percent, moderate-to-severe exacerbations (those requiring corticosteroids) were reduced by 63 percent. The average length of an exacerbation declined by 37 percent, while antibiotics prescriptions declined 56 percent. And hospitalizations were reduced by 90 percent.

The findings were published in the April issue of the journal Chest.

Many of the study authors reported ties with Hunter Immunology Ltd., an Australian biopharmaceutical company that makes HI-164OV.

More information

The U.S. National Heart, Lung, and Blood Institute has more on COPD.



SOURCES: Norman H. Edelman, M.D., chief medical officer, American Lung Association, Washington, D.C.; Len Horovitz, M.D., pulmonary specialist, Lenox Hill Hospital, New York City; April 2010, Chest


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Genetic Engineering Raises Hope for Lyme Disease Vaccine
2. Only 1 in 4 Americans Got H1N1 Vaccine
3. Clues Found to How Different Flu Vaccines Work
4. GSK Joins Global Vaccine Alliance to Help Prevent Millions of Children from Contracting Pneumococcal Disease in the Worlds Poorest Countries
5. Miles for Hope’s Moving Towards A Cure(SM) Brain Tumor Walk in Boston Raising Funds for Brain Tumor Vaccine and Massachusetts General Hospital
6. FDA Asks Docs to Suspend Using Glaxo Rotavirus Vaccine
7. GlaxoSmithKline Statement on New Information Relating to Manufacture of Rotarix (Rotavirus Vaccine)
8. Keeping up with the neighbors speeds vaccine use
9. Young Kids to Benefit From Broader Pneumococcal Vaccine
10. The Pediatric Dengue Vaccine Initiative Introduces www.DengueWatch.org - a News hub for Tracking Dengue Fever Epidemics Worldwide
11. 1 in 5 At-Risk U.S. Babies Doesnt Get Hepatitis B Vaccine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... ... established the certification process to promote standards of excellence for the field of ... scheduled for March 22 – 25, 2018 in Orlando, Florida at the Omni ...
(Date:10/13/2017)... ... ... Apple Rehab Shelton Lakes , which specializes in the delivery of ... part of a disaster drill on October 3rd. , Apple Rehab participated with the ... as well as the Connecticut Long Term Care Mutual Aid Plan (LTC-MAP). The ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... Global Healthcare ... scenic Alexandria Park in Milford, NJ. This free event, sponsored by Global Healthcare ... activity. The fun run is geared towards children of all ages; it is ...
(Date:10/13/2017)... ... ... “The Journey: From the Mountains to the Mission Field”: the story of a missionary ... Journey: From the Mountains to the Mission Field” is the creation of published author, ... ages and currently teaches a class of ladies at her church, which she has ...
(Date:10/12/2017)... ... October 12, 2017 , ... Planet Fitness, one of ... announced today its plans to open a flagship location in Covington, LA at 401 ... Rooms To Go store next to Office Depot in the Holiday Square shopping center. ...
Breaking Medicine News(10 mins):
(Date:10/4/2017)... , Oct. 4, 2017 ... single-use, self-contained, illuminating medical devices, today announced regulatory ... Health Surveillance Agency (or Agência Nacional de Vigilância ... first single-use, cordless surgical retractor with integrated LED ... optimal access, illumination and exposure of a tissue ...
(Date:10/2/2017)... -- AllianceRx Walgreens Prime, the combined central specialty pharmacy and ... manager Prime Therapeutics LLC (Prime), today officially began the ... of new signage at its headquarters in ... few other company-owned facilities across the country. This also ... whom will begin to see the AllianceRx Walgreens Prime ...
(Date:9/28/2017)... CHICAGO , Sept. 28, 2017 Hill-Rom ... quarter 2017 earnings conference call and webcast on Friday, ... 8:00 a.m. (EDT) and ending at approximately 8:30 a.m. ... to discussing the company,s 2017 financial performance and guidance ... growth opportunities, initiatives to enhance operational performance, and long-range ...
Breaking Medicine Technology: